Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Amgen’s Humira Biosimilar Recommended for EMA Approval

XTALKS VITALS NEWS

Biosimilar

If the EMA takes the advice of the CHMP, Amjevita could be approved to treat a number of conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.

Share this!

February 1, 2017 | by Sarah Hand, M.Sc.

An advisory committee to the European Medicines Agency (EMA) recently recommended the approval of Amgen’s biosimilar of AbbVie’s Humira. The drug was originally submitted for European approval back in late 2015, with the biosimilar – marketed as Amjevita – approved by the US Food and Drug Administration (FDA) in September of 2016.

If the EMA takes the advice of the CHMP, Amjevita could be approved to treat a number of conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. According to the committee, “studies have shown that Amgevita has comparable quality, safety and efficacy to Humira.”



In addition to Amjevita, the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended the approval of seven other drugs. The committee also announced that Sandoz had withdrawn its application for approval of its biosimilar of Amgen's Neulasta.

Neulasta is not Amgen’s top selling product, however biosimilar competition for the biologic could certainly have an effect on sales of the drug. As Novartis’ generic unit, Sandoz, has withdrawn their application for now, Amgen will have more time to plan for the potential launch of the copycat biologic in the future.

However, Novartis has plans to resubmit the Neulasta biosimilar to the EMA in late 2017. The drugmaker also plans to resubmit the drug for approval by the FDA in 2018.


Keywords: Biosimilar, Biologic, EMA


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Better Meal Planning for Diabetics Using a Predictive Blood Sugar App

April 21, 2017 - A new app could allow people with type 2 diabetes to make predictions about the impact of a meal on their blood sugar levels, before they even take a bite.

Featured In: Life Science News


Bacterial Biomarkers Could Make Diagnosing Colorectal Cancer Less Invasive

April 20, 2017 - Researchers at The University of Texas Health Science Center at Houston School of Public Health have identified specific strains of gut bacteria which have been associated with colorectal cancer.

Featured In: Life Science News


Weetabix Cereal Sold to Post in £1.4 Billion Deal

April 20, 2017 - The cereal was sold by Shanghai-based Bright Food, which acquired a controlling stake in the company in 2012.

Featured In: Food News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation

REGISTER FOR THESE WEBINARS

Electronic Informed Consent: 2017 Industry Survey Results


Critical CRO Oversight Metrics: How to Establish the Right Metrics and Monitor them in Real-Time


The Modernization of eCOA Technology for Clinical Trials


Developing a Biological Safety Evaluation


Copyright © 2016-2017 Honeycomb Worldwide Inc.